The Arvinas (ARVN) board of directors has authorized the repurchase of up to $100M of the company’s common stock. Following the actions announced, Arvinas is reaffirming its cash runway guidance into the second half of 2028. The company currently expects that this runway will support multiple opportunities to deliver value from clinical-stage programs derived from the company’s de-risked and clinically validated platform technology. These opportunities include clinical data readouts from its Protac degraders ARV-102, ARV-393, and ARV-806.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN: